Pacira BioSciences Competitors

Johnson & Johnson (NYSE:JNJ) and Pacira BioSciences (NASDAQ:PCRX) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, valuation, risk, analyst recommendations and dividends.

Earnings & Valuation

This table compares Johnson & Johnson and Pacira BioSciences' gross revenue, earnings per share and valuation.

Johnson & Johnson has higher revenue and earnings than Pacira BioSciences. Johnson & Johnson is trading at a lower price-to-earnings ratio than Pacira BioSciences, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current recommendations and price targets for Johnson & Johnson and Pacira BioSciences, as provided by MarketBeat.com.

Johnson & Johnson currently has a consensus target price of $178.9333, suggesting a potential upside of 14.63%. Pacira BioSciences has a consensus target price of $76.0909, suggesting a potential upside of 9.96%. Given Johnson & Johnson's stronger consensus rating and higher probable upside, research analysts plainly believe Johnson & Johnson is more favorable than Pacira BioSciences.

Profitability

This table compares Johnson & Johnson and Pacira BioSciences' net margins, return on equity and return on assets.

Insider and Institutional Ownership

67.3% of Johnson & Johnson shares are held by institutional investors. 0.3% of Johnson & Johnson shares are held by insiders. Comparatively, 5.8% of Pacira BioSciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Volatility & Risk

Johnson & Johnson has a beta of 0.7, meaning that its share price is 30% less volatile than the S&P 500. Comparatively, Pacira BioSciences has a beta of 1.27, meaning that its share price is 27% more volatile than the S&P 500.

Summary

Johnson & Johnson beats Pacira BioSciences on 10 of the 14 factors compared between the two stocks.

Pacira BioSciences (NASDAQ:PCRX) and Eli Lilly and (NYSE:LLY) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, profitability, dividends, earnings and analyst recommendations.

Earnings and Valuation

This table compares Pacira BioSciences and Eli Lilly and's gross revenue, earnings per share (EPS) and valuation.

Eli Lilly and has higher revenue and earnings than Pacira BioSciences. Eli Lilly and is trading at a lower price-to-earnings ratio than Pacira BioSciences, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Pacira BioSciences and Eli Lilly and, as reported by MarketBeat.com.

Pacira BioSciences currently has a consensus price target of $76.0909, suggesting a potential upside of 9.96%. Eli Lilly and has a consensus price target of $192.60, suggesting a potential downside of 6.92%. Given Pacira BioSciences' higher probable upside, equities research analysts clearly believe Pacira BioSciences is more favorable than Eli Lilly and.

Profitability

This table compares Pacira BioSciences and Eli Lilly and's net margins, return on equity and return on assets.

Insider and Institutional Ownership

75.6% of Eli Lilly and shares are held by institutional investors. 5.8% of Pacira BioSciences shares are held by company insiders. Comparatively, 0.1% of Eli Lilly and shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Volatility and Risk

Pacira BioSciences has a beta of 1.27, indicating that its stock price is 27% more volatile than the S&P 500. Comparatively, Eli Lilly and has a beta of 0.37, indicating that its stock price is 63% less volatile than the S&P 500.

Summary

Eli Lilly and beats Pacira BioSciences on 11 of the 15 factors compared between the two stocks.

Pacira BioSciences (NASDAQ:PCRX) and Pfizer (NYSE:PFE) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, profitability, dividends, earnings and analyst recommendations.

Earnings and Valuation

This table compares Pacira BioSciences and Pfizer's gross revenue, earnings per share (EPS) and valuation.

Pfizer has higher revenue and earnings than Pacira BioSciences. Pfizer is trading at a lower price-to-earnings ratio than Pacira BioSciences, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Pacira BioSciences and Pfizer, as reported by MarketBeat.com.

Pacira BioSciences currently has a consensus price target of $76.0909, suggesting a potential upside of 9.96%. Pfizer has a consensus price target of $39.5333, suggesting a potential upside of 14.96%. Given Pfizer's higher probable upside, analysts clearly believe Pfizer is more favorable than Pacira BioSciences.

Profitability

This table compares Pacira BioSciences and Pfizer's net margins, return on equity and return on assets.

Insider and Institutional Ownership

67.4% of Pfizer shares are held by institutional investors. 5.8% of Pacira BioSciences shares are held by company insiders. Comparatively, 0.1% of Pfizer shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Volatility and Risk

Pacira BioSciences has a beta of 1.27, indicating that its stock price is 27% more volatile than the S&P 500. Comparatively, Pfizer has a beta of 0.7, indicating that its stock price is 30% less volatile than the S&P 500.

Pacira BioSciences (NASDAQ:PCRX) and AbbVie (NYSE:ABBV) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, profitability, dividends, earnings and analyst recommendations.

Earnings and Valuation

This table compares Pacira BioSciences and AbbVie's gross revenue, earnings per share (EPS) and valuation.

AbbVie has higher revenue and earnings than Pacira BioSciences. AbbVie is trading at a lower price-to-earnings ratio than Pacira BioSciences, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Pacira BioSciences and AbbVie, as reported by MarketBeat.com.

Pacira BioSciences currently has a consensus price target of $76.0909, suggesting a potential upside of 9.96%. AbbVie has a consensus price target of $115.50, suggesting a potential upside of 8.25%. Given Pacira BioSciences' higher probable upside, equities research analysts clearly believe Pacira BioSciences is more favorable than AbbVie.

Profitability

This table compares Pacira BioSciences and AbbVie's net margins, return on equity and return on assets.

Insider and Institutional Ownership

67.5% of AbbVie shares are held by institutional investors. 5.8% of Pacira BioSciences shares are held by company insiders. Comparatively, 0.1% of AbbVie shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Volatility and Risk

Pacira BioSciences has a beta of 1.27, indicating that its stock price is 27% more volatile than the S&P 500. Comparatively, AbbVie has a beta of 0.84, indicating that its stock price is 16% less volatile than the S&P 500.

Summary

AbbVie beats Pacira BioSciences on 8 of the 14 factors compared between the two stocks.

Pacira BioSciences (NASDAQ:PCRX) and Merck & Co., Inc. (NYSE:MRK) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, profitability, dividends, earnings and analyst recommendations.

Earnings and Valuation

This table compares Pacira BioSciences and Merck & Co., Inc.'s gross revenue, earnings per share (EPS) and valuation.

Merck & Co., Inc. has higher revenue and earnings than Pacira BioSciences. Merck & Co., Inc. is trading at a lower price-to-earnings ratio than Pacira BioSciences, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Pacira BioSciences and Merck & Co., Inc., as reported by MarketBeat.com.

Pacira BioSciences currently has a consensus price target of $76.0909, suggesting a potential upside of 9.96%. Merck & Co., Inc. has a consensus price target of $95.3571, suggesting a potential upside of 30.39%. Given Merck & Co., Inc.'s stronger consensus rating and higher probable upside, analysts clearly believe Merck & Co., Inc. is more favorable than Pacira BioSciences.

Profitability

This table compares Pacira BioSciences and Merck & Co., Inc.'s net margins, return on equity and return on assets.

Insider and Institutional Ownership

72.9% of Merck & Co., Inc. shares are held by institutional investors. 5.8% of Pacira BioSciences shares are held by company insiders. Comparatively, 0.3% of Merck & Co., Inc. shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Volatility and Risk

Pacira BioSciences has a beta of 1.27, indicating that its stock price is 27% more volatile than the S&P 500. Comparatively, Merck & Co., Inc. has a beta of 0.43, indicating that its stock price is 57% less volatile than the S&P 500.

Summary

Merck & Co., Inc. beats Pacira BioSciences on 9 of the 14 factors compared between the two stocks.

Pacira BioSciences (NASDAQ:PCRX) and Bristol-Myers Squibb (NYSE:BMY) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, profitability, dividends, earnings and analyst recommendations.

Earnings and Valuation

This table compares Pacira BioSciences and Bristol-Myers Squibb's gross revenue, earnings per share (EPS) and valuation.

Bristol-Myers Squibb has higher revenue and earnings than Pacira BioSciences. Bristol-Myers Squibb is trading at a lower price-to-earnings ratio than Pacira BioSciences, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Pacira BioSciences and Bristol-Myers Squibb, as reported by MarketBeat.com.

Pacira BioSciences currently has a consensus price target of $76.0909, suggesting a potential upside of 9.96%. Bristol-Myers Squibb has a consensus price target of $74.6429, suggesting a potential upside of 23.52%. Given Bristol-Myers Squibb's stronger consensus rating and higher probable upside, analysts clearly believe Bristol-Myers Squibb is more favorable than Pacira BioSciences.

Profitability

This table compares Pacira BioSciences and Bristol-Myers Squibb's net margins, return on equity and return on assets.

Insider and Institutional Ownership

72.4% of Bristol-Myers Squibb shares are held by institutional investors. 5.8% of Pacira BioSciences shares are held by company insiders. Comparatively, 0.1% of Bristol-Myers Squibb shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Volatility and Risk

Pacira BioSciences has a beta of 1.27, indicating that its stock price is 27% more volatile than the S&P 500. Comparatively, Bristol-Myers Squibb has a beta of 0.67, indicating that its stock price is 33% less volatile than the S&P 500.

Summary

Bristol-Myers Squibb beats Pacira BioSciences on 10 of the 15 factors compared between the two stocks.